Skip to main content

Table 2 Association and interaction between serum urate-associated single nucleotide polymorphisms and sex for gout risk

From: Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank

GeneSNPEffect alleleWomen
n = 188,221
Men
n = 171,655
Gene-sex interaction
P
Effect allele absent
Referent OR
Effect allele present
OR (95% CI)
Effect allele absent
OR (95% CI)
Effect allele present
OR (95% CI)
Loci replicated by Kottgen
ABCG2rs2231142T11.62 (1.35–1.94)11.99 (10.81–13.30)28.65 (25.73–31.90)4.59 × 10−5
SLC2A9rs12498742A14.12 (2.05–8.30)18.09 (8.85–36.98)55.62 (27.77–111.37)0.42
GCKRrs1260326T11.42 (1.18–1.70)13.80 (11.77–16.18)19.08 (16.33–22.29)0.80
SLC17A3rs1165151T10.76 (0.64–0.91)13.15 (11.38–15.20)10.56 (9.16–12.17)0.60
SLC22A12rs478607A10.78 (0.48–1.28)13.96 (8.44–23.09)10.57 (6.53–17.11)0.90
PDZK1rs1471633A10.92 (0.77–1.10)10.54 (9.00–12.34)13.61 (11.68–15.85)3.67 × 10−4
INHBErs3741414T10.82 (0.69–0.98)13.57 (12.16–15.15)11.06 (9.89–12.38)0.92
SLC16A9rs1171614T10.95 (0.80–1.12)14.28 (12.78–15.96)11.74 (10.48–13.16)0.11
SLC22A11rs2078267T10.78 (0.65–0.95)13.59 (11.42–16.17)10.57 (8.93–12.51)0.96
RREB1rs675209T11.23 (1.04–1.45)14.28 (12.62–16.16)15.74 (13.90–17.82)0.23
Loci reported by Kottgen
PKLRrs11264341T10.82 (0.69–0.97)13.09 (11.4–15.08)11.34 (9.87–13.02)0.57
INHBBrs17050272A11.10 (0.93–1.32)14.25 (12.26–16.57)14.54 (12.54–16.85)0.40
ACVR2Ars2307394T10.99 (0.75–1.31)14.72 (11.13–19.48)13.28 (10.14–17.40)0.53
MUSTN1rs6770152T10.96 (0.78–1.19)15.29 (12.50–18.70)12.75 (10.49–15.51)0.21
TMEM171rs17632159C10.76 (0.65–0.90)12.81 (11.39–14.41)11.31 (10.06–12.73)0.11
VEGFArs729761T10.99 (0.84–1.17)13.89 (12.29–15.70)13.03 (11.53–14.74)0.55
MLXIPLrs1178977A11.71 (1.00–2.90)17.96 (10.42–30.95)22.86 (13.50–38.72)0.30
PRKAG2rs10480300T10.97 (0.82–1.15)12.74 (11.31–14.35)14.07 (12.50–15.85)0.15
STC1rs17786744A11.36 (1.06–1.74)17.59 (13.86–22.33)17.64 (13.99–22.25)0.02
HNF4Grs2941484T11.11 (0.92–1.33)14.00 (11.89–16.49)14.78 (12.59–17.34)0.62
ASAH2rs10821905A10.96 (0.80–1.15)12.86 (11.57–14.29)14.63 (13.12–16.33)0.07
LTBP3rs642803T10.92 (0.77–1.10)13.81 (11.80–16.16)12.33 (10.58–14.38)0.76
PTPN11rs653178T10.85 (0.70–1.02)13.30 (11.24–15.74)11.52 (9.78–13.57)0.82
NRG4rs1394125A11.02 (0.86–1.21)13.06 (11.40–14.98)14.17 (12.38–16.21)0.52
IGF1Rrs6598541A11.06 (0.89–1.25)13.05 (11.38–14.96)14.48 (12.65–16.56)0.59
NFAT5rs7193778T11.12 (0.63–1.98)20.20 (11.23–36.35)14.91 (8.44–26.35)0.17
MAFrs7188445A10.96 (0.82–1.14)13.64 (12.01–15.48)12.91 (11.38–14.65)0.84
HLFrs7224610A10.90 (0.72–1.12)13.76 (11.13–17.00)12.13 (9.89–14.89)0.88
C17ORF82rs2079742T10.92 (0.52–1.64)10.34 (5.65–18.93)12.54 (7.09–22.19)0.38
PRPSAP1rs164009A11.32 (1.02–1.71)17.00 (13.25–21.82)17.27 (13.55–22.01)0.05
  1. Association and interaction data are reported according to effect allele presence or absence
  2. Data are adjusted by age, body mass index, diuretic use, and renal failure
  3. Experiment-wide significance is defined as P < 0.0017
  4. CI confidence interval, OR odds ratio, SNP single nucleotide polymorphism